The raw feed
Latest filings
Every transaction from every Form 4, as filed, newest first. Open-market buys (P) and sells (S) become signals; the rest is shown for completeness.
| Date | Company | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Isabel Kalofonos Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -55,000 | $41.21 | $2.3M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Common Stock | -58,286 | $85.00 | $5.0M | 79,650 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Common Stock | -79,650 | $85.00 | $6.8M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -90,514 | $83.09 | $7.5M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -74,540 | $75.72 | $5.6M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,250 | $59.81 | $3.4M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -60,000 | $62.39 | $3.7M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -85,000 | $69.71 | $5.9M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,000 | $61.81 | $927k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -77,000 | $64.98 | $5.0M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -110,000 | $65.36 | $7.2M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -87,000 | $41.49 | $3.6M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -65,000 | $48.14 | $3.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -47,000 | $41.21 | $1.9M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Tobin Schilke Chief Financial & Infra. Ofcr. | DDisposition to issuer Common Stock | -7,956 | $85.00 | $676k | 71,471 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Tobin Schilke Chief Financial & Infra. Ofcr. | DDisposition to issuer Common Stock | -71,471 | $85.00 | $6.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Tobin Schilke Chief Financial & Infra. Ofcr. | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | $51.25 | $4.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Tobin Schilke Chief Financial & Infra. Ofcr. | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | $41.21 | $2.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stock | -248,043 | $85.00 | $21M | 176,663 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Spouse | -1,000 | $85.00 | $85k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 1 | -136,805 | $85.00 | $12M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 2 | -106,000 | $85.00 | $9.0M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 3 | -110,000 | $85.00 | $9.3M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 4 | -100,000 | $85.00 | $8.5M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 5 | -111,100 | $85.00 | $9.4M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 6 | -111,100 | $85.00 | $9.4M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 7 | -111,100 | $85.00 | $9.4M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 8 | -111,100 | $85.00 | $9.4M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Charitable Trust | -80,000 | $85.00 | $6.8M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stock | -176,663 | $85.00 | $15M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -172,281 | $59.81 | $10M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -195,578 | $62.39 | $12M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -259,058 | $69.71 | $18M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -244,205 | $64.98 | $16M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -287,700 | $65.36 | $19M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -240,000 | $41.49 | $10.0M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -313,000 | $48.14 | $15M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -228,000 | $41.21 | $9.4M | 0 | 44 d ago |
| Aug 31, 2026 | EXOD Exodus Movement, Inc. | Jon Paul Richardson Chief Executive Officer | DDisposition to issuer Class A Common Stock | -273,278 | $0.00 | $0 | 513,440 | 44 d ago |
| Aug 31, 2026 | EXOD Exodus Movement, Inc. | Daniel Castagnoli President, 3ZERO | DDisposition to issuer Class A Common Stock | -233,218 | $0.00 | $0 | 477,207 | 44 d ago |
| Aug 31, 2026 | CNK Cinemark Holdings, Inc. | Sean Gamble Chief Executive Officer | DDisposition to issuer Common Stockindirect: Joint Revocable Trust of Sean Robert Gamble & Luminita Spetcu10b5-1 | -7,191 | $35.99 | $259k | 439,487 | 44 d ago |
| Sep 1, 2026 | NCSM NCS Multistage Holdings, Inc. | Robert Nipper director | DDisposition to issuer Common Stock | -36,676 | - | - | 0 | 44 d ago |
| Sep 1, 2026 | NCSM NCS Multistage Holdings, Inc. | Robert Nipper director | DDisposition to issuer Common Stockindirect: By Nipper Family Limited Partnership | -88,596 | - | - | 0 | 44 d ago |
| Sep 1, 2026 | NCSM NCS Multistage Holdings, Inc. | Michael L Morrison See Remarks | DDisposition to issuer Common Stock | -11,049 | - | - | 0 | 44 d ago |
| Sep 1, 2026 | NCSM NCS Multistage Holdings, Inc. | Michael L Morrison See Remarks | DDisposition to issuer Equivalent Stock Unitsderivative | -3,898 | - | - | 0 | 44 d ago |
| Sep 1, 2026 | NCSM NCS Multistage Holdings, Inc. | Michael L Morrison See Remarks | DDisposition to issuer Equivalent Stock Unitsderivative | -2,145 | - | - | 0 | 44 d ago |
| Sep 1, 2026 | NCSM NCS Multistage Holdings, Inc. | Michael L Morrison See Remarks | DDisposition to issuer Equivalent Stock Unitsderivative | -2,463 | - | - | 0 | 44 d ago |
| Sep 1, 2026 | NCSM NCS Multistage Holdings, Inc. | Michael L Morrison See Remarks | DDisposition to issuer Performance Stock Unitsderivative | -11,696 | - | - | 0 | 44 d ago |
| Sep 1, 2026 | NCSM NCS Multistage Holdings, Inc. | Michael L Morrison See Remarks | DDisposition to issuer Performance Stock Unitsderivative | -6,435 | - | - | 0 | 44 d ago |
| Sep 1, 2026 | NCSM NCS Multistage Holdings, Inc. | Michael L Morrison See Remarks | DDisposition to issuer Performance Stock Unitsderivative | -4,978 | - | - | 0 | 44 d ago |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.